• 1
    Lavie G, Valentine F, Levin B, et al. Studies of the mechanisms of action of the antiretroviral agents hypericin and pseudohypericin. Proc Natl Acad Sci U S A. 1989; 86: 5963-5967.
  • 2
    Jacobson JM, Feinman L, Liebes L, et al. Pharmacokinetics, safety, and antiviral effects of hypericin, a derivative of St. John's wort plant, in patients with chronic hepatitis C virus infection. Antimicrob Agents Chemother. 2001; 45: 517-524.
  • 3
    Couldwell WT, Antel JP, Yong VW. Protein kinase C activity correlates with the growth rate of malignant gliomas: part II. Effects of glioma mitogens and modulators of protein kinase C. Neurosurgery. 1992; 31: 717-724; discussion 724.
  • 4
    Couldwell WT, Gopalakrishna R, Hinton DR, et al. Hypericin: a potential antiglioma therapy. Neurosurgery. 1994; 35: 705-709; discussion 709-710.
  • 5
    Blank M, Mandel M, Keisari Y, Meruelo D, Lavie G. Enhanced ubiquitinylation of heat shock protein 90 as a potential mechanism for mitotic cell death in cancer cells induced with hypericin. Cancer Res. 2003; 63: 8241-8247.
  • 6
    Fox FE, Niu Z, Tobia A, Rook AH. Photoactivated hypericin is an anti-proliferative agent that induces a high rate of apoptotic death of normal, transformed, and malignant T lymphocytes: implications for the treatment of cutaneous lymphoproliferative and inflammatory disorders. J Invest Dermatol. 1998; 111: 327-332.
  • 7
    Lavie G, Mandel M, Hazan S, et al. Anti-angiogenic activities of hypericin in vivo: potential for ophthalmologic applications. Angiogenesis. 2005; 8: 35-42.
  • 8
    Alecu M, Ursaciuc C, Halalau F, et al. Photodynamic treatment of basal cell carcinoma and squamous cell carcinoma with hypericin. Anticancer Res. 1998; 18: 4651-4654.
  • 9
    Rook AH, Wood GS, Duvic M, Vonderheid EC, Tobia A, Cabana B. A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis. J Am Acad Dermatol. 2010; 63: 984-990.
  • 10
    Kacerovska D, Pizinger K, Majer F, Smid F. Photodynamic therapy of nonmelanoma skin cancer with topical hypericum perforatum extract—a pilot study. Photochem Photobiol. 2008; 84: 779-785.
  • 11
    Liebes L, Mazur Y, Freeman D, et al. A method for the quantitation of hypericin, an antiviral agent, in biological fluids by high-performance liquid chromatography. Anal Biochem. 1991; 195: 77-85.
  • 12
    National Cancer Institute Cancer Therapy Evaluation Program. Common Toxicity Criteria Manual, version 2.0. Washington, DC: National Cancer Institute; 1999.
  • 13
    Couldwell WT, Antel JP, Apuzzo ML, Yong VW. Inhibition of growth of established human glioma cell lines by modulators of the protein kinase-C system. J Neurosurg. 1990; 73: 594-600.
  • 14
    Couldwell WT, Uhm JH, Antel JP, Yong VW. Enhanced protein kinase C activity correlates with the growth rate of malignant gliomas in vitro. Neurosurgery. 1991; 29: 880-886; discussion 886-887.
  • 15
    Huang LE, Gu J, Schau M, Bunn HF. Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A. 1998; 95: 7987-7992.
  • 16
    Anker L, Gopalakrishna R, Law R, Jones K, Couldwell W. Hypericin: an antitumor agent. Drugs Future. 1995; 20: 511-517.
  • 17
    Brandes AA, Tosoni A, Cavallo G, et al. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Br J Cancer. 2006; 95: 1155-1160.
  • 18
    Brem H, Mahaley MS, Jr, Vick NA, et al. Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg. 1991; 74: 441-446.
  • 19
    Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009; 27: 4733-4740.
  • 20
    Graff JR, McNulty AM, Hanna KR, et al. The protein kinase C beta-selective inhibitor, enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res. 2005; 65: 7462-7469.
  • 21
    Kreisl TN, Kim L, Moore K, et al. A phase I trial of enzastaurin in patients with recurrent gliomas. Clin Cancer Res. 2009; 15: 3617-3623.
  • 22
    Propper DJ, Macaulay V, O'Byrne KJ, et al. A phase II study of bryostatin 1 in metastatic malignant melanoma. Br J Cancer. 1998; 78: 1337-1341.
  • 23
    Gupta V, Su YS, Wang W, et al. Enhancement of glioblastoma cell killing by combination treatment with temozolomide and tamoxifen or hypericin [serial online]. Neurosurg Focus. 2006; 20(4): e20.
  • 24
    Zhang W, Anker L, Law RE, et al. Enhancement of radiosensitivity in human malignant glioma cells by hypericin in vitro. Clin Cancer Res. 1996; 2: 843-846.
  • 25
    Chen TC, Su S, Fry D, Liebes L. Combination therapy with irinotecan and protein kinase C inhibitors in malignant glioma. Cancer. 2003; 97: 2363-2373.
  • 26
    Hopfner M, Maaser K, Theiss A, et al. Hypericin activated by an incoherent light source has photodynamic effects on esophageal cancer cells. Int J Colorectal Dis. 2003; 18: 239-247.
  • 27
    Yee KK, Soo KC, Olivo M. Anti-angiogenic effects of hypericin-photodynamic therapy in combination with Celebrex in the treatment of human nasopharyngeal carcinoma. Int J Mol Med. 2005; 16: 993-1002.